With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.
At Nestlé Health Science, we’re advancing nutritional therapy to change the approach of managing your health. Behind our pioneering company are people who are driving breakthroughs and innovating for impact. Here, you have the chance to change the course of health and your career. Our people are exploring new territory and breaking new ground in areas such as GI, critical care, surgery, oncology, healthy ageing, food allergy, obesity, brain health and pediatrics. They are changing the way doctors think about meeting the nutritional needs of patients, and the way patients and consumers manage their own health. They know the faces, hear the stories and celebrate the successes of people who had their lives transformed thanks to Nestlé Health Science solutions. Be part of a journey that changes the course of health.
Advanced Accelerator Applications is a pharmaceutical group specialized in the field of nuclear medicine.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.
Pioneer Surgical Technology is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.